RxDoctor Payments DataLook up a doctor →

Michael Cosgrove, MD

Pain Medicine · Huntsville, ALNPI 1750459616

Payments from drug & device makers

$25,163in general payments, 2019–2025

Across 654 payments — averaging $38.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$20K
  • Saluda Medical Americas, Inc.$3K
  • Amgen$432
  • Scilex Pharmaceuticals Inc.$375
  • Zyla Life Sciences, Inc.$195
  • Redhill Biopharma Inc.$171
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$5,04020%
  • Speaking & faculty fees$2,80011%
  • Travel & lodging$2,2349%
  • Food & beverage$14,33257%
  • Education$7563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,163 in reported general payments places this provider in the 95th percentile of 77 pain medicine providers in Alabama.

See all pain medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$269,544
Medicare patients
901
Services billed
2,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen4,889$97,658
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,048$47,522
Gabapentin2,080$28,066
OxycontinOxycodone Hcl37$27,876
Buprenorphine88$23,359
Pregabalin1,040$21,608
Xtampza ErOxycodone Myristate31$13,563
BelbucaBuprenorphine Hcl20$11,123
Oxycodone Hcl401$5,820
Tramadol Hcl527$4,934
Hydrocodone-IbuprofenHydrocodone/Ibuprofen12$3,066
Tramadol Hcl ErTramadol Hcl37$2,985
Morphine Sulfate ErMorphine Sulfate139$2,912
Lidocaine13$1,833
Diclofenac Sodium50$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$78$24,68651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 pain medicine providers in Alabama.

Other pain medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →